Michael Ellenbogen - Sep 15, 2025 Form 4 Insider Report for Evolv Technologies Holdings, Inc. (EVLV)

Role
Founder & Chief Innovation Ofc, Director
Signature
/s/ Rachel Roy, Attorney-in-fact for Michael Ellenbogen
Stock symbol
EVLV
Transactions as of
Sep 15, 2025
Transactions value $
-$663,724
Form type
4
Date filed
9/17/2025, 04:02 PM
Previous filing
Jun 25, 2025
Next filing
Oct 17, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ellenbogen Michael Founder & Chief Innovation Ofc, Director C/O EVOLV TECHNOLOGIES, INC., 500 TOTTEN POND ROAD, 4TH FLOOR, WALTHAM /s/ Rachel Roy, Attorney-in-fact for Michael Ellenbogen 2025-09-17 0001869206

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EVLV Class A Common Stock Options Exercise $19.4K +80.7K +3.87% $0.24 2.16M Sep 15, 2025 Direct
transaction EVLV Class A Common Stock Sale -$683K -80.7K -3.73% $8.46 2.08M Sep 15, 2025 Direct F1, F2
holding EVLV Class A Common Stock 151K Sep 15, 2025 Held by Family Horizon Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVLV Stock Option (Right to Buy) Options Exercise $0 -80.7K -4.74% $0.00 1.62M Sep 15, 2025 Class A Common Stock 80.7K $0.24 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on June 12, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.34 to $8.80. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The option vested and became exercisable as to 25% on January 31, 2018 and vested in 36 equal monthly installments thereafter.